OP0033 FIBROBLAST GENE, FKBP7 INDUCED BY Ca2+ DEPENDENT ER STRESS ASSOCIATED WITH CLINICAL OUTCOME IN RHEUMATOID ARTHRITIS AND CROHN’S DISEASE; MULTI-CENTRE GWAS AND FUNCTIONAL STUDIES

Background:Studying which biological pathways are involved in reaching remission in auto-immune diseases could highlight possible targetable mechanisms. Rheumatoid arthritis (RA) is the ideal model disease to study this hypothesis due to well-defined and widely-used measures of disease activity.Obje...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 83; no. Suppl 1; pp. 28 - 29
Main Authors Maurits, M. P., Cameron, A., Jelinsky, S., Blüml, S., Abasolo, L., Askling, J., Barton, A., Böhringer, S., Cope, A., De, S., Emery, P., Eyre, S., Gaddi, V. P., González-Álvaro, I., Goodyear, C. S., Hu, X., Huizinga, T., Johannesson, M., Jurado-Zapata, S., Klareskog, L., Lendrem, D., Martin, P., Mc Innes, I. B., Micheroli, R., Morgan, A., Morton, F., Naamane, N., Nagafuchi, Y., Orozco, G., Padyukov, L., Paterson, C., Pitzalis, C., Plant, D., Porter, D., Reynard, L., Rodriguez Rodriguez, L., Sieghart, D., Studenic, P., Taylor, J., Toes, R. E. M., Van den Akker, E. B., Van der Helm – van Mil, A. H. M., Vaskimo, L., Verstappen, S., Westerlind, H., Isaacs, J., Lewis, M., Pratt, A., Ospelt, C., Winkler, A., Thomas, R., Knevel, R.
Format Journal Article
LanguageEnglish
Published Kidlington BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2024
Elsevier B.V
Elsevier Limited
Subjects
Online AccessGet full text
ISSN0003-4967
1468-2060
DOI10.1136/annrheumdis-2024-eular.2788

Cover

Abstract Background:Studying which biological pathways are involved in reaching remission in auto-immune diseases could highlight possible targetable mechanisms. Rheumatoid arthritis (RA) is the ideal model disease to study this hypothesis due to well-defined and widely-used measures of disease activity.Objectives:To increase understanding of the mechanisms and biological pathways underlying autoimmune disease remission through GWAS directed functional studies.Methods:The RTCure network collected genetic data of 5,622 deeply phenotyped treatment naive RA patients with longitudinal disease activity data. Data were uniformly QC’ed and imputed using the Haplotype Reference Consortium reference panel. We carried out a GWAS per dataset with DAS28-CRP below 2.6 at 6 months as our outcome, including top 10 principal components, age and sex as covariates. We combined the results using a fixed-effect meta-analysis. SNPs were mapped to genes using Open Targets Genetics. We assessed gene expression using single cell RNAseq of synovial biopsies (AMP-I [1], PEAC [2], Zurich and Queensland) and eQTL data of circulating CD4+ T-cells from untreated RA patients (NEAC) [3]. To investigate the role of Ca2+ induced endoplasmic reticulum (ER) stress on FKBP7, Rheumatoid Arthritis fibroblast-like synoviocytes (RA-FLS) HPRT-knockout cells were stimulated with 400nM thapsigargin (Tg) for 24 hours and cell lysate was collected for RNA analysis. Relative mRNA expression of FKBP7 and stress-related genes CHOP, Grp78 and sXBP1 was calculated against the housekeeper β-actin.Results:Our top hit (P < 5 x 10-8), rs16866400 (Figure 1A-B), has the strongest e-, p- and sQTL association with FK506 binding protein 7 (FKBP7), whose relevance to auto-immunity is understudied. The association was not driven by CCP status, HLA or DMARD usage. The FKBP7 protein is an ER resident chaperone regulating the folding of proteins. Both public and proprietary data show that FKBP7 is differentially overexpressed in a key RA tissue, fibroblast-like synoviocytes (FLS), rather than in circulating B- and T-cells(Figure 1C-E). FKBP7 expression in blood associated both with baseline and change in DAS28-CRP. (Figure 1F) Our studies show that in response to Tg induced Ca2+ ER stress, but not other stressors such as tunicamycin or pro-inflammatory cytokines, FKBP7 was upregulated in RA FLS (Figure 2). FKBP7 has been found to regulate the NOD2 pathway[4]. As this is strongly associated with inflammatory immune responses in Crohn’s Disease (CD), we checked published Crohn’s progression GWAS data for colonic FKPB7 eQTLs.[5] 22% of the colonic FKBP7 eQTLs (GTEx) included in the CD GWAS were significantly (P < 0.05) associated with CD severity.Conclusion:We found the ER resident molecular chaperone encoding gene FKBP7 to link to both RA remission and CD severity. Our functional studies demonstrate a role for the chaperone in the regulation of Ca2+ ER stress and highlights FKBP7 as an interesting gene for further research related to the induction of remission. Elucidating the underlying mechanisms will both increase our understanding of auto-immune pathophysiology as well as facilitate the discovery of novel treatment targets.REFERENCES:[1] Zhang et al, 2019, Nat Imm.[2] Lewis et al, 2019, Cell Rep.[3] Thalayasingam et al, 2018, A&R.[4] Warner et al, 2013, Sci. Signal.[5] Lee, J. C., Biasci, D., et al., 2017, Nat Genet.Figure 1.(A) Manhattan plot, dashed line at p = 5 x 10-8, (B) forest plot of rs16866400 locus, (C) FKBP7 expression in fibroblasts, monocytes, T-cells and B-cells in RA, osteoarthritis and healthy participants [1] (n = 55 RA patients), (D-E) expression across cell types in arthritis patients (n=355 RA patients and n = 26 synovial tissues of 5 arthritides respectively) and (F) association between FKBP7 levels in blood and DAS28-CRP (response).Figure 2.Thapsigargin treated (24h) vs untreated RA-FLS HPRTKO. Relative mRNA expression of (a) FKBP7 and stress genes (b) CHOP, (c) Grp78 and (d) sXBP1 calculated against β-actin. n=8/groupAcknowledgements:We would like to acknowledge support by SPIDeRR Horizon EU (grant 101080711), RTCure, the IMI2 JU (grant 777357), ZonMW (grant 90719069), MRC/Versus Arthritis MATURA Consortium, Versus Arthritis Inflammatory Arthritis Centre Versus Arthritis, NIHR Newcastle Biomedical Research Centre, NIHR Leeds BioMedical Research Centre, UK Medical Research Council (TACERA) and Pfizer.Disclosure of Interests:Marc P. Maurits: None declared, Amy Cameron: None declared, Scott Jelinsky No conflict of interest applies to this abstract, Stephan Blüml: None declared, Lydia Abasolo: None declared, Johan Askling: None declared, Anne Barton: None declared, Stefan Böhringer: None declared, Andrew Cope: None declared, Saurav De No conflict of interest applies to this abstract, Paul Emery: None declared, Stephen Eyre: None declared, Vasanthi Priyadarshini Gaddi: None declared, Isidoro González-Álvaro: None declared, Carl S Goodyear: None declared, Xinli Hu No conflict of interest applies to this abstract, Tom Huizinga: None declared, Martina Johannesson: None declared, Samantha Jurado-Zapata: None declared, Lars Klareskog: None declared, Dennis Lendrem: None declared, Paul Martin: None declared, Iain B. Mc Innes: None declared, Raphael Micheroli: None declared, Ann Morgan: None declared, Fraser Morton: None declared, Najib Naamane: None declared, Yasuo Nagafuchi: None declared, Gisela Orozco: None declared, Leonid Padyukov: None declared, Caron Paterson: None declared, Costantino Pitzalis: None declared, Darren Plant: None declared, Duncan Porter: None declared, Louise Reynard: None declared, Luis Rodriguez Rodriguez: None declared, Daniela Sieghart: None declared, Paul Studenic: None declared, John Taylor: None declared, Rene E.M. Toes: None declared, Erik B. van den Akker: None declared, Annette H.M. van der Helm – van Mil: None declared, Lotta Vaskimo: None declared, Suzanne Verstappen: None declared, Helga Westerlind: None declared, John Isaacs: None declared, Myles Lewis: None declared, Arthur Pratt: None declared, Caroline Ospelt: None declared, Aaron Winkler No conflict of interest applies to this abstract, Ranjeny Thomas: None declared, Rachel Knevel: None declared.
AbstractList Background:Studying which biological pathways are involved in reaching remission in auto-immune diseases could highlight possible targetable mechanisms. Rheumatoid arthritis (RA) is the ideal model disease to study this hypothesis due to well-defined and widely-used measures of disease activity.Objectives:To increase understanding of the mechanisms and biological pathways underlying autoimmune disease remission through GWAS directed functional studies.Methods:The RTCure network collected genetic data of 5,622 deeply phenotyped treatment naive RA patients with longitudinal disease activity data. Data were uniformly QC’ed and imputed using the Haplotype Reference Consortium reference panel. We carried out a GWAS per dataset with DAS28-CRP below 2.6 at 6 months as our outcome, including top 10 principal components, age and sex as covariates. We combined the results using a fixed-effect meta-analysis. SNPs were mapped to genes using Open Targets Genetics. We assessed gene expression using single cell RNAseq of synovial biopsies (AMP-I [1], PEAC [2], Zurich and Queensland) and eQTL data of circulating CD4+ T-cells from untreated RA patients (NEAC) [3]. To investigate the role of Ca2+ induced endoplasmic reticulum (ER) stress on FKBP7, Rheumatoid Arthritis fibroblast-like synoviocytes (RA-FLS) HPRT-knockout cells were stimulated with 400nM thapsigargin (Tg) for 24 hours and cell lysate was collected for RNA analysis. Relative mRNA expression of FKBP7 and stress-related genes CHOP, Grp78 and sXBP1 was calculated against the housekeeper β-actin.Results:Our top hit (P < 5 x 10-8), rs16866400 (Figure 1A-B), has the strongest e-, p- and sQTL association with FK506 binding protein 7 (FKBP7), whose relevance to auto-immunity is understudied. The association was not driven by CCP status, HLA or DMARD usage. The FKBP7 protein is an ER resident chaperone regulating the folding of proteins. Both public and proprietary data show that FKBP7 is differentially overexpressed in a key RA tissue, fibroblast-like synoviocytes (FLS), rather than in circulating B- and T-cells(Figure 1C-E). FKBP7 expression in blood associated both with baseline and change in DAS28-CRP. (Figure 1F) Our studies show that in response to Tg induced Ca2+ ER stress, but not other stressors such as tunicamycin or pro-inflammatory cytokines, FKBP7 was upregulated in RA FLS (Figure 2). FKBP7 has been found to regulate the NOD2 pathway[4]. As this is strongly associated with inflammatory immune responses in Crohn’s Disease (CD), we checked published Crohn’s progression GWAS data for colonic FKPB7 eQTLs.[5] 22% of the colonic FKBP7 eQTLs (GTEx) included in the CD GWAS were significantly (P < 0.05) associated with CD severity.Conclusion:We found the ER resident molecular chaperone encoding gene FKBP7 to link to both RA remission and CD severity. Our functional studies demonstrate a role for the chaperone in the regulation of Ca2+ ER stress and highlights FKBP7 as an interesting gene for further research related to the induction of remission. Elucidating the underlying mechanisms will both increase our understanding of auto-immune pathophysiology as well as facilitate the discovery of novel treatment targets.REFERENCES:[1] Zhang et al, 2019, Nat Imm.[2] Lewis et al, 2019, Cell Rep.[3] Thalayasingam et al, 2018, A&R.[4] Warner et al, 2013, Sci. Signal.[5] Lee, J. C., Biasci, D., et al., 2017, Nat Genet.Figure 1.(A) Manhattan plot, dashed line at p = 5 x 10-8, (B) forest plot of rs16866400 locus, (C) FKBP7 expression in fibroblasts, monocytes, T-cells and B-cells in RA, osteoarthritis and healthy participants [1] (n = 55 RA patients), (D-E) expression across cell types in arthritis patients (n=355 RA patients and n = 26 synovial tissues of 5 arthritides respectively) and (F) association between FKBP7 levels in blood and DAS28-CRP (response).Figure 2.Thapsigargin treated (24h) vs untreated RA-FLS HPRTKO. Relative mRNA expression of (a) FKBP7 and stress genes (b) CHOP, (c) Grp78 and (d) sXBP1 calculated against β-actin. n=8/groupAcknowledgements:We would like to acknowledge support by SPIDeRR Horizon EU (grant 101080711), RTCure, the IMI2 JU (grant 777357), ZonMW (grant 90719069), MRC/Versus Arthritis MATURA Consortium, Versus Arthritis Inflammatory Arthritis Centre Versus Arthritis, NIHR Newcastle Biomedical Research Centre, NIHR Leeds BioMedical Research Centre, UK Medical Research Council (TACERA) and Pfizer.Disclosure of Interests:Marc P. Maurits: None declared, Amy Cameron: None declared, Scott Jelinsky No conflict of interest applies to this abstract, Stephan Blüml: None declared, Lydia Abasolo: None declared, Johan Askling: None declared, Anne Barton: None declared, Stefan Böhringer: None declared, Andrew Cope: None declared, Saurav De No conflict of interest applies to this abstract, Paul Emery: None declared, Stephen Eyre: None declared, Vasanthi Priyadarshini Gaddi: None declared, Isidoro González-Álvaro: None declared, Carl S Goodyear: None declared, Xinli Hu No conflict of interest applies to this abstract, Tom Huizinga: None declared, Martina Johannesson: None declared, Samantha Jurado-Zapata: None declared, Lars Klareskog: None declared, Dennis Lendrem: None declared, Paul Martin: None declared, Iain B. Mc Innes: None declared, Raphael Micheroli: None declared, Ann Morgan: None declared, Fraser Morton: None declared, Najib Naamane: None declared, Yasuo Nagafuchi: None declared, Gisela Orozco: None declared, Leonid Padyukov: None declared, Caron Paterson: None declared, Costantino Pitzalis: None declared, Darren Plant: None declared, Duncan Porter: None declared, Louise Reynard: None declared, Luis Rodriguez Rodriguez: None declared, Daniela Sieghart: None declared, Paul Studenic: None declared, John Taylor: None declared, Rene E.M. Toes: None declared, Erik B. van den Akker: None declared, Annette H.M. van der Helm – van Mil: None declared, Lotta Vaskimo: None declared, Suzanne Verstappen: None declared, Helga Westerlind: None declared, John Isaacs: None declared, Myles Lewis: None declared, Arthur Pratt: None declared, Caroline Ospelt: None declared, Aaron Winkler No conflict of interest applies to this abstract, Ranjeny Thomas: None declared, Rachel Knevel: None declared.
Studying which biological pathways are involved in reaching remission in auto-immune diseases could highlight possible targetable mechanisms. Rheumatoid arthritis (RA) is the ideal model disease to study this hypothesis due to well-defined and widely-used measures of disease activity. To increase understanding of the mechanisms and biological pathways underlying autoimmune disease remission through GWAS directed functional studies. The RTCure network collected genetic data of 5,622 deeply phenotyped treatment naive RA patients with longitudinal disease activity data. Data were uniformly QC’ed and imputed using the Haplotype Reference Consortium reference panel. We carried out a GWAS per dataset with DAS28-CRP below 2.6 at 6 months as our outcome, including top 10 principal components, age and sex as covariates. We combined the results using a fixed-effect meta-analysis. SNPs were mapped to genes using Open Targets Genetics. We assessed gene expression using single cell RNAseq of synovial biopsies (AMP-I [1], PEAC [2], Zurich and Queensland) and eQTL data of circulating CD4+ T-cells from untreated RA patients (NEAC) [3]. To investigate the role of Ca2+ induced endoplasmic reticulum (ER) stress on FKBP7, Rheumatoid Arthritis fibroblast-like synoviocytes (RA-FLS) HPRT-knockout cells were stimulated with 400nM thapsigargin (Tg) for 24 hours and cell lysate was collected for RNA analysis. Relative mRNA expression of FKBP7 and stress-related genes CHOP, Grp78 and sXBP1 was calculated against the housekeeper β-actin. Our top hit (P < 5 x 10-8), rs16866400 (Figure 1A-B), has the strongest e-, p- and sQTL association with FK506 binding protein 7 (FKBP7), whose relevance to auto-immunity is understudied. The association was not driven by CCP status, HLA or DMARD usage. The FKBP7 protein is an ER resident chaperone regulating the folding of proteins. Both public and proprietary data show that FKBP7 is differentially overexpressed in a key RA tissue, fibroblast-like synoviocytes (FLS), rather than in circulating B- and T-cells(Figure 1C-E). FKBP7 expression in blood associated both with baseline and change in DAS28-CRP. (Figure 1F) Our studies show that in response to Tg induced Ca2+ ER stress, but not other stressors such as tunicamycin or pro-inflammatory cytokines, FKBP7 was upregulated in RA FLS (Figure 2). FKBP7 has been found to regulate the NOD2 pathway[4]. As this is strongly associated with inflammatory immune responses in Crohn’s Disease (CD), we checked published Crohn’s progression GWAS data for colonic FKPB7 eQTLs.[5] 22% of the colonic FKBP7 eQTLs (GTEx) included in the CD GWAS were significantly (P < 0.05) associated with CD severity. We found the ER resident molecular chaperone encoding gene FKBP7 to link to both RA remission and CD severity. Our functional studies demonstrate a role for the chaperone in the regulation of Ca2+ ER stress and highlights FKBP7 as an interesting gene for further research related to the induction of remission. Elucidating the underlying mechanisms will both increase our understanding of auto-immune pathophysiology as well as facilitate the discovery of novel treatment targets. [1] Zhang et al, 2019, Nat Imm. [2] Lewis et al, 2019, Cell Rep. [3] Thalayasingam et al, 2018, A&R. [4] Warner et al, 2013, Sci. Signal. [5] Lee, J. C., Biasci, D., et al., 2017, Nat Genet. We would like to acknowledge support by SPIDeRR Horizon EU (grant 101080711), RTCure, the IMI2 JU (grant 777357), ZonMW (grant 90719069), MRC/Versus Arthritis MATURA Consortium, Versus Arthritis Inflammatory Arthritis Centre Versus Arthritis, NIHR Newcastle Biomedical Research Centre, NIHR Leeds BioMedical Research Centre, UK Medical Research Council (TACERA) and Pfizer. Marc P. Maurits: None declared, Amy Cameron: None declared, Scott Jelinsky No conflict of interest applies to this abstract, Stephan Blüml: None declared, Lydia Abasolo: None declared, Johan Askling: None declared, Anne Barton: None declared, Stefan Böhringer: None declared, Andrew Cope: None declared, Saurav De No conflict of interest applies to this abstract, Paul Emery: None declared, Stephen Eyre: None declared, Vasanthi Priyadarshini Gaddi: None declared, Isidoro González-Álvaro: None declared, Carl S Goodyear: None declared, Xinli Hu No conflict of interest applies to this abstract, Tom Huizinga: None declared, Martina Johannesson: None declared, Samantha Jurado-Zapata: None declared, Lars Klareskog: None declared, Dennis Lendrem: None declared, Paul Martin: None declared, Iain B. Mc Innes: None declared, Raphael Micheroli: None declared, Ann Morgan: None declared, Fraser Morton: None declared, Najib Naamane: None declared, Yasuo Nagafuchi: None declared, Gisela Orozco: None declared, Leonid Padyukov: None declared, Caron Paterson: None declared, Costantino Pitzalis: None declared, Darren Plant: None declared, Duncan Porter: None declared, Louise Reynard: None declared, Luis Rodriguez Rodriguez: None declared, Daniela Sieghart: None declared, Paul Studenic: None declared, John Taylor: None declared, Rene E.M. Toes: None declared, Erik B. van den Akker: None declared, Annette H.M. van der Helm – van Mil: None declared, Lotta Vaskimo: None declared, Suzanne Verstappen: None declared, Helga Westerlind: None declared, John Isaacs: None declared, Myles Lewis: None declared, Arthur Pratt: None declared, Caroline Ospelt: None declared, Aaron Winkler No conflict of interest applies to this abstract, Ranjeny Thomas: None declared, Rachel Knevel: None declared. [Display omitted] [Display omitted]
Background:Studying which biological pathways are involved in reaching remission in auto-immune diseases could highlight possible targetable mechanisms. Rheumatoid arthritis (RA) is the ideal model disease to study this hypothesis due to well-defined and widely-used measures of disease activity.Objectives:To increase understanding of the mechanisms and biological pathways underlying autoimmune disease remission through GWAS directed functional studies.Methods:The RTCure network collected genetic data of 5,622 deeply phenotyped treatment naive RA patients with longitudinal disease activity data. Data were uniformly QC’ed and imputed using the Haplotype Reference Consortium reference panel. We carried out a GWAS per dataset with DAS28-CRP below 2.6 at 6 months as our outcome, including top 10 principal components, age and sex as covariates. We combined the results using a fixed-effect meta-analysis. SNPs were mapped to genes using Open Targets Genetics. We assessed gene expression using single cell RNAseq of synovial biopsies (AMP-I [1], PEAC [2], Zurich and Queensland) and eQTL data of circulating CD4+ T-cells from untreated RA patients (NEAC) [3]. To investigate the role of Ca2+ induced endoplasmic reticulum (ER) stress on FKBP7, Rheumatoid Arthritis fibroblast-like synoviocytes (RA-FLS) HPRT-knockout cells were stimulated with 400nM thapsigargin (Tg) for 24 hours and cell lysate was collected for RNA analysis. Relative mRNA expression of FKBP7 and stress-related genes CHOP, Grp78 and sXBP1 was calculated against the housekeeper β-actin.Results:Our top hit (P < 5 x 10-8), rs16866400 (Figure 1A-B), has the strongest e-, p- and sQTL association with FK506 binding protein 7 (FKBP7), whose relevance to auto-immunity is understudied. The association was not driven by CCP status, HLA or DMARD usage. The FKBP7 protein is an ER resident chaperone regulating the folding of proteins. Both public and proprietary data show that FKBP7 is differentially overexpressed in a key RA tissue, fibroblast-like synoviocytes (FLS), rather than in circulating B- and T-cells(Figure 1C-E). FKBP7 expression in blood associated both with baseline and change in DAS28-CRP. (Figure 1F) Our studies show that in response to Tg induced Ca2+ ER stress, but not other stressors such as tunicamycin or pro-inflammatory cytokines, FKBP7 was upregulated in RA FLS (Figure 2). FKBP7 has been found to regulate the NOD2 pathway[4]. As this is strongly associated with inflammatory immune responses in Crohn’s Disease (CD), we checked published Crohn’s progression GWAS data for colonic FKPB7 eQTLs.[5] 22% of the colonic FKBP7 eQTLs (GTEx) included in the CD GWAS were significantly (P < 0.05) associated with CD severity.Conclusion:We found the ER resident molecular chaperone encoding gene FKBP7 to link to both RA remission and CD severity. Our functional studies demonstrate a role for the chaperone in the regulation of Ca2+ ER stress and highlights FKBP7 as an interesting gene for further research related to the induction of remission. Elucidating the underlying mechanisms will both increase our understanding of auto-immune pathophysiology as well as facilitate the discovery of novel treatment targets.REFERENCES:[1] Zhang et al, 2019, Nat Imm.[2] Lewis et al, 2019, Cell Rep.[3] Thalayasingam et al, 2018, A&R.[4] Warner et al, 2013, Sci. Signal.[5] Lee, J. C., Biasci, D., et al., 2017, Nat Genet.Figure 1.(A) Manhattan plot, dashed line at p = 5 x 10-8, (B) forest plot of rs16866400 locus, (C) FKBP7 expression in fibroblasts, monocytes, T-cells and B-cells in RA, osteoarthritis and healthy participants [1] (n = 55 RA patients), (D-E) expression across cell types in arthritis patients (n=355 RA patients and n = 26 synovial tissues of 5 arthritides respectively) and (F) association between FKBP7 levels in blood and DAS28-CRP (response).[Figure omitted. See PDF]Figure 2.Thapsigargin treated (24h) vs untreated RA-FLS HPRTKO. Relative mRNA expression of (a) FKBP7 and stress genes (b) CHOP, (c) Grp78 and (d) sXBP1 calculated against β-actin. n=8/group[Figure omitted. See PDF]Acknowledgements:We would like to acknowledge support by SPIDeRR Horizon EU (grant 101080711), RTCure, the IMI2 JU (grant 777357), ZonMW (grant 90719069), MRC/Versus Arthritis MATURA Consortium, Versus Arthritis Inflammatory Arthritis Centre Versus Arthritis, NIHR Newcastle Biomedical Research Centre, NIHR Leeds BioMedical Research Centre, UK Medical Research Council (TACERA) and Pfizer.Disclosure of Interests:Marc P. Maurits: None declared, Amy Cameron: None declared, Scott Jelinsky No conflict of interest applies to this abstract, Stephan Blüml: None declared, Lydia Abasolo: None declared, Johan Askling: None declared, Anne Barton: None declared, Stefan Böhringer: None declared, Andrew Cope: None declared, Saurav De No conflict of interest applies to this abstract, Paul Emery: None declared, Stephen Eyre: None declared, Vasanthi Priyadarshini Gaddi: None declared, Isidoro González-Álvaro: None declared, Carl S Goodyear: None declared, Xinli Hu No conflict of interest applies to this abstract, Tom Huizinga: None declared, Martina Johannesson: None declared, Samantha Jurado-Zapata: None declared, Lars Klareskog: None declared, Dennis Lendrem: None declared, Paul Martin: None declared, Iain B. Mc Innes: None declared, Raphael Micheroli: None declared, Ann Morgan: None declared, Fraser Morton: None declared, Najib Naamane: None declared, Yasuo Nagafuchi: None declared, Gisela Orozco: None declared, Leonid Padyukov: None declared, Caron Paterson: None declared, Costantino Pitzalis: None declared, Darren Plant: None declared, Duncan Porter: None declared, Louise Reynard: None declared, Luis Rodriguez Rodriguez: None declared, Daniela Sieghart: None declared, Paul Studenic: None declared, John Taylor: None declared, Rene E.M. Toes: None declared, Erik B. van den Akker: None declared, Annette H.M. van der Helm – van Mil: None declared, Lotta Vaskimo: None declared, Suzanne Verstappen: None declared, Helga Westerlind: None declared, John Isaacs: None declared, Myles Lewis: None declared, Arthur Pratt: None declared, Caroline Ospelt: None declared, Aaron Winkler No conflict of interest applies to this abstract, Ranjeny Thomas: None declared, Rachel Knevel: None declared.
Author Martin, P.
Porter, D.
Taylor, J.
Barton, A.
Ospelt, C.
Huizinga, T.
Klareskog, L.
Cope, A.
Pitzalis, C.
Pratt, A.
Nagafuchi, Y.
Goodyear, C. S.
González-Álvaro, I.
Hu, X.
Morton, F.
Van den Akker, E. B.
Jelinsky, S.
Eyre, S.
Emery, P.
Toes, R. E. M.
Micheroli, R.
Westerlind, H.
Naamane, N.
Reynard, L.
Van der Helm – van Mil, A. H. M.
Jurado-Zapata, S.
Morgan, A.
Rodriguez Rodriguez, L.
Winkler, A.
Lendrem, D.
Böhringer, S.
Cameron, A.
Mc Innes, I. B.
Orozco, G.
Thomas, R.
Paterson, C.
Gaddi, V. P.
Studenic, P.
Lewis, M.
Plant, D.
Isaacs, J.
Abasolo, L.
Knevel, R.
Blüml, S.
Askling, J.
Padyukov, L.
Johannesson, M.
Sieghart, D.
Verstappen, S.
Maurits, M. P.
Vaskimo, L.
De, S.
Author_xml – sequence: 1
  givenname: M. P.
  surname: Maurits
  fullname: Maurits, M. P.
  organization: Leiden University Medical Center, Rheumatology, Leiden, Netherlands
– sequence: 2
  givenname: A.
  surname: Cameron
  fullname: Cameron, A.
  organization: University of Queensland, Brisbane, Australia
– sequence: 3
  givenname: S.
  surname: Jelinsky
  fullname: Jelinsky, S.
  organization: Pfizer, New York City, United States of America
– sequence: 4
  givenname: S.
  surname: Blüml
  fullname: Blüml, S.
  organization: Medical University of Vienna, Vienna, Austria
– sequence: 5
  givenname: L.
  surname: Abasolo
  fullname: Abasolo, L.
  organization: Hospital Clínico San Carlos, Madrid, Spain
– sequence: 6
  givenname: J.
  surname: Askling
  fullname: Askling, J.
  organization: Karolinska Institutet, Stockholm, Sweden
– sequence: 7
  givenname: A.
  surname: Barton
  fullname: Barton, A.
  organization: University of Manchester, Manchester, United Kingdom
– sequence: 8
  givenname: S.
  surname: Böhringer
  fullname: Böhringer, S.
  organization: Leiden University Medical Center, Medical Statistics, Leiden, Netherlands
– sequence: 9
  givenname: A.
  surname: Cope
  fullname: Cope, A.
  organization: King’s College London, London, United Kingdom
– sequence: 10
  givenname: S.
  surname: De
  fullname: De, S.
  organization: Pfizer, New York City, United States of America
– sequence: 11
  givenname: P.
  surname: Emery
  fullname: Emery, P.
  organization: University of Leeds, Leeds, United Kingdom
– sequence: 12
  givenname: S.
  surname: Eyre
  fullname: Eyre, S.
  organization: University of Manchester, Manchester, United Kingdom
– sequence: 13
  givenname: V. P.
  surname: Gaddi
  fullname: Gaddi, V. P.
  organization: University of Manchester, Manchester, United Kingdom
– sequence: 14
  givenname: I.
  surname: González-Álvaro
  fullname: González-Álvaro, I.
  organization: Hospital Universitario de La Princesa, Madrid, Spain
– sequence: 15
  givenname: C. S.
  surname: Goodyear
  fullname: Goodyear, C. S.
  organization: University of Glasgow, Glasgow, United Kingdom
– sequence: 16
  givenname: X.
  surname: Hu
  fullname: Hu, X.
  organization: Pfizer, New York City, United States of America
– sequence: 17
  givenname: T.
  surname: Huizinga
  fullname: Huizinga, T.
  organization: Leiden University Medical Center, Rheumatology, Leiden, Netherlands
– sequence: 18
  givenname: M.
  surname: Johannesson
  fullname: Johannesson, M.
  organization: Karolinska Institutet, Stockholm, Sweden
– sequence: 19
  givenname: S.
  surname: Jurado-Zapata
  fullname: Jurado-Zapata, S.
  organization: Leiden University Medical Center, Rheumatology, Leiden, Netherlands
– sequence: 20
  givenname: L.
  surname: Klareskog
  fullname: Klareskog, L.
  organization: Karolinska Institutet, Stockholm, Sweden
– sequence: 21
  givenname: D.
  surname: Lendrem
  fullname: Lendrem, D.
  organization: Newcastle University, Newcastle, United Kingdom
– sequence: 22
  givenname: P.
  surname: Martin
  fullname: Martin, P.
  organization: University of Manchester, Manchester, United Kingdom
– sequence: 23
  givenname: I. B.
  surname: Mc Innes
  fullname: Mc Innes, I. B.
  organization: University of Glasgow, Glasgow, United Kingdom
– sequence: 24
  givenname: R.
  surname: Micheroli
  fullname: Micheroli, R.
  organization: University Hospital Zurich, Zurich, Switzerland
– sequence: 25
  givenname: A.
  surname: Morgan
  fullname: Morgan, A.
  organization: University of Leeds, Leeds, United Kingdom
– sequence: 26
  givenname: F.
  surname: Morton
  fullname: Morton, F.
  organization: University of Glasgow, Glasgow, United Kingdom
– sequence: 27
  givenname: N.
  surname: Naamane
  fullname: Naamane, N.
  organization: Newcastle University, Newcastle, United Kingdom
– sequence: 28
  givenname: Y.
  surname: Nagafuchi
  fullname: Nagafuchi, Y.
  organization: University of Tokyo, Tokyo, Japan
– sequence: 29
  givenname: G.
  surname: Orozco
  fullname: Orozco, G.
  organization: University of Manchester, Manchester, United Kingdom
– sequence: 30
  givenname: L.
  surname: Padyukov
  fullname: Padyukov, L.
  organization: Karolinska Institutet, Stockholm, Sweden
– sequence: 31
  givenname: C.
  surname: Paterson
  fullname: Paterson, C.
  organization: University of Glasgow, Glasgow, United Kingdom
– sequence: 32
  givenname: C.
  surname: Pitzalis
  fullname: Pitzalis, C.
  organization: Queen Mary University of London, London, United Kingdom
– sequence: 33
  givenname: D.
  surname: Plant
  fullname: Plant, D.
  organization: University of Manchester, Manchester, United Kingdom
– sequence: 34
  givenname: D.
  surname: Porter
  fullname: Porter, D.
  organization: University of Glasgow, Glasgow, United Kingdom
– sequence: 35
  givenname: L.
  surname: Reynard
  fullname: Reynard, L.
  organization: Newcastle University, Newcastle, United Kingdom
– sequence: 36
  givenname: L.
  surname: Rodriguez Rodriguez
  fullname: Rodriguez Rodriguez, L.
  organization: Hospital Clínico San Carlos, Madrid, Spain
– sequence: 37
  givenname: D.
  surname: Sieghart
  fullname: Sieghart, D.
  organization: Medical University of Vienna, Vienna, Austria
– sequence: 38
  givenname: P.
  surname: Studenic
  fullname: Studenic, P.
  organization: Medical University of Vienna, Vienna, Austria
– sequence: 39
  givenname: J.
  surname: Taylor
  fullname: Taylor, J.
  organization: University of Leeds, Leeds, United Kingdom
– sequence: 40
  givenname: R. E. M.
  surname: Toes
  fullname: Toes, R. E. M.
  organization: Leiden University Medical Center, Rheumatology, Leiden, Netherlands
– sequence: 41
  givenname: E. B.
  surname: Van den Akker
  fullname: Van den Akker, E. B.
  organization: Leiden University Medical Center, Biomedical Data Sciences, Leiden, Netherlands
– sequence: 42
  givenname: A. H. M.
  surname: Van der Helm – van Mil
  fullname: Van der Helm – van Mil, A. H. M.
  organization: Leiden University Medical Center, Rheumatology, Leiden, Netherlands
– sequence: 43
  givenname: L.
  surname: Vaskimo
  fullname: Vaskimo, L.
  organization: Leiden University Medical Center, Rheumatology, Leiden, Netherlands
– sequence: 44
  givenname: S.
  surname: Verstappen
  fullname: Verstappen, S.
  organization: University of Manchester, Manchester, United Kingdom
– sequence: 45
  givenname: H.
  surname: Westerlind
  fullname: Westerlind, H.
  organization: Karolinska Institutet, Stockholm, Sweden
– sequence: 46
  givenname: J.
  surname: Isaacs
  fullname: Isaacs, J.
  organization: Newcastle University, Newcastle, United Kingdom
– sequence: 47
  givenname: M.
  surname: Lewis
  fullname: Lewis, M.
  organization: Queen Mary University of London, London, United Kingdom
– sequence: 48
  givenname: A.
  surname: Pratt
  fullname: Pratt, A.
  organization: Newcastle University, Newcastle, United Kingdom
– sequence: 49
  givenname: C.
  surname: Ospelt
  fullname: Ospelt, C.
  organization: University Hospital Zurich, Zurich, Switzerland
– sequence: 50
  givenname: A.
  surname: Winkler
  fullname: Winkler, A.
  organization: Pfizer, New York City, United States of America
– sequence: 51
  givenname: R.
  surname: Thomas
  fullname: Thomas, R.
  organization: University of Queensland, Brisbane, Australia
– sequence: 52
  givenname: R.
  surname: Knevel
  fullname: Knevel, R.
  organization: Leiden University Medical Center, Rheumatology, Leiden, Netherlands
BookMark eNqNkU9u1DAYxS1UJKaFO1jqElLsOJM46iqTeCYWmWQUO6pYWfnjERl1kuJ0kNh1wyG4C6fpSfAQJFh2Zdl-7_c--12Ci2EcNADXGN1gTPyP9TCYL_p07PrJcZHrOfp0X5sbN6D0FVhgz6f22EcXYIEQIo4X-sEbcDlNB7tFFNMF-FXs7A15fvqx5quyWGWRkHDDcvYBrj-tdgHkeVLFLIGrzzCu3fcwYTuWJyyXkJVQyJIJASMhiphH0sruuExhnPGcx1EGi0rGxZZZCCxTVm0jWfAERqVMSy65NeYJjMsizZ-ffgqYcMEiwW7htsokd2IbUjK4uYtm4brKY8mL3HKFrBLOxFvwel_fT_rd3_UKVGsm49TJis0532lwiJBDPIpqhAIPk7Z19w1CbUu6cB94etk0lHQoXDaUBnW7DGvq1y6mQRciHCwb34oxuQLXM_fBjF9PenpUh_FkBhupCEYotP9NkFXdzqrWjNNk9F49mP5Ym-8KI3WuS_1XlzrXpf7Upc51WTeb3do-5FuvjZraXg-t7nqj20fVjf0LOcHMaY6Hf2O-xPkbVPeuXQ
ContentType Journal Article
Copyright Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
2024 © Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc.
2024 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Copyright_xml – notice: Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
– notice: 2024 © Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc.
– notice: 2024 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
DBID AAYXX
CITATION
K9.
DOI 10.1136/annrheumdis-2024-eular.2788
DatabaseName CrossRef
ProQuest Health & Medical Complete (Alumni)
DatabaseTitle CrossRef
ProQuest Health & Medical Complete (Alumni)
DatabaseTitleList

ProQuest Health & Medical Complete (Alumni)
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2060
EndPage 29
ExternalDocumentID 10_1136_annrheumdis_2024_eular_2788
S0003496724150285
annrheumdis
GroupedDBID ---
.55
.GJ
.VT
169
23M
2WC
39C
3O-
4.4
40O
53G
5GY
5RE
5VS
6J9
7X7
7~S
88E
88I
8AF
8FE
8FH
8FI
8FJ
8R4
8R5
AAHLL
AAKAS
AAOJX
AAWJN
AAWTL
AAXUO
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABTFR
ABUWG
ABVAJ
ACGFO
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACOAB
ACOFX
ACPRK
ACQSR
ACTZY
ADBBV
ADCEG
ADFRT
ADUGQ
ADZCM
AEKJL
AENEX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
AZQEC
BAWUL
BBNVY
BENPR
BHPHI
BKNYI
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C1A
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DWQXO
E3Z
EBS
EJD
F5P
FDB
FYUFA
GNUQQ
H13
HAJ
HCIFZ
HMCUK
HYE
HZ~
IAO
IEA
IHR
INH
INR
IOF
ITC
J5H
K9-
KQ8
L7B
LK8
M0R
M1P
M2P
M7P
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
RWL
RXW
TAE
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
VVN
W2D
W8F
WH7
WOQ
X6Y
X7M
YFH
YOC
YQY
ZGI
ZXP
0R~
AAFWJ
AALRI
PHGZM
PJZUB
PPXIY
PQGLB
AAYXX
CITATION
K9.
ID FETCH-LOGICAL-b1900-3480a007413cc2fb00cc3d9f74e5bb83d095b887ac59a86a2187d90175b6b0013
ISSN 0003-4967
IngestDate Fri Jul 25 10:58:53 EDT 2025
Thu Jul 31 00:38:46 EDT 2025
Sat Aug 23 17:13:03 EDT 2025
Thu Apr 24 22:50:08 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue Suppl 1
Keywords Fibroblasts
Genetics
Remission
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-b1900-3480a007413cc2fb00cc3d9f74e5bb83d095b887ac59a86a2187d90175b6b0013
Notes EULAR 2024 European Congress of Rheumatology, 12-15 June. Vienna, Austria
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
PQID 3100927830
PQPubID 2041045
PageCount 2
ParticipantIDs proquest_journals_3100927830
crossref_primary_10_1136_annrheumdis_2024_eular_2788
elsevier_sciencedirect_doi_10_1136_annrheumdis_2024_eular_2788
bmj_journals_10_1136_annrheumdis_2024_eular_2788
PublicationCentury 2000
PublicationDate 2024-June
June 2024
2024-06-00
20240601
PublicationDateYYYYMMDD 2024-06-01
PublicationDate_xml – month: 06
  year: 2024
  text: 2024-June
PublicationDecade 2020
PublicationPlace Kidlington
PublicationPlace_xml – name: Kidlington
PublicationTitle Annals of the rheumatic diseases
PublicationTitleAbbrev Ann Rheum Dis
PublicationYear 2024
Publisher BMJ Publishing Group Ltd and European League Against Rheumatism
Elsevier B.V
Elsevier Limited
Publisher_xml – name: BMJ Publishing Group Ltd and European League Against Rheumatism
– name: Elsevier B.V
– name: Elsevier Limited
SSID ssj0000818
Score 2.4508007
Snippet Background:Studying which biological pathways are involved in reaching remission in auto-immune diseases could highlight possible targetable mechanisms....
Studying which biological pathways are involved in reaching remission in auto-immune diseases could highlight possible targetable mechanisms. Rheumatoid...
SourceID proquest
crossref
elsevier
bmj
SourceType Aggregation Database
Index Database
Publisher
StartPage 28
SubjectTerms Actin
Autoimmune diseases
Biomedical research
Biopsy
Blood levels
Calcium (reticular)
CD4 antigen
Conflicts of interest
Consortia
Crohn's disease
Endoplasmic reticulum
Fibroblasts
Gene expression
Genes
Genetics
Haplotypes
Immunological diseases
Inflammatory bowel diseases
Lymphocytes B
Lymphocytes T
Medical research
Medical treatment
Monocytes
NOD2 protein
Osteoarthritis
Patients
Protein folding
Remission
Remission (Medicine)
Rheumatoid arthritis
Scientific Abstracts
Tacrolimus
Tacrolimus-binding protein
Title OP0033 FIBROBLAST GENE, FKBP7 INDUCED BY Ca2+ DEPENDENT ER STRESS ASSOCIATED WITH CLINICAL OUTCOME IN RHEUMATOID ARTHRITIS AND CROHN’S DISEASE; MULTI-CENTRE GWAS AND FUNCTIONAL STUDIES
URI https://ard.bmj.com/content/83/Suppl_1/28.full
https://dx.doi.org/10.1136/annrheumdis-2024-eular.2788
https://www.proquest.com/docview/3100927830
Volume 83
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: AUTh Library subscriptions: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1468-2060
  dateEnd: 20241231
  omitProxy: true
  ssIdentifier: ssj0000818
  issn: 0003-4967
  databaseCode: BENPR
  dateStart: 19390101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1468-2060
  dateEnd: 20241231
  omitProxy: true
  ssIdentifier: ssj0000818
  issn: 0003-4967
  databaseCode: 7X7
  dateStart: 19390101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FVqq4IJ6ipVQrAafFwbEdP4SE5FewS-JEfoj0ZNmOLYTagEpy4cTf4K_wc7jzH5hdrx9qAYVerGiVHe9mvux8szs7g9DzKi-VKqsKIS8kTVDAQgqAG3Bcs6rMxEopxIJF-Qaqlyiny_FyMPjVi1rabvJh8fWP90puolVoA73SW7L_odlWKDTAZ9AvPEHD8NxJx_MFLZJGJr4Vzq2pGcWERqIxPvrOWmjED5zEdh1inRE7k15IFnHchRs4bhATusEU05-_zuzom7CEgTsfe8Se-gHLkjBPYns-o0XpSei5ycyM575DgAF7oR_7EctMZYdzL2giJoyIOH7kmpFLKwPMkmnsCza8LHTJ2_dm3WGSBDZPwNtno9fyObPQxw_ltk4py8-RWgdgRrMhbeqd8uFi2DtJKS95ley28ZReued7xFHbap3TGAHLvjjvtfPtD0npwrTaJV0WFKOu6dEs6brcX5P1nnWvt1eu2w2ZJ0xmE4M5CexdJQ0FHkqarnfmsgkRuGJF29hG5lXJ7KZ3IyylwlImLKXCbqF9SVNVWnBDW2odcdBHelPgkc7oAD3jY3v1j5EBKcovPv6NVl0hGIw1xXfRHe7uYLPG7j00KNf30cGMB3Q8QD9qCOMOwphC-CVmAMYcwNg6wwBgglv4YjfENXxxB19M4Ysb-GIOXxCCO_jiFr4Y0IgZfH9--x5hDtzXuA9bTGHLvtjBFnPYPkTJxI1tT-DlRIQcWC-wDUUXM0ah5aKQKrA3RSGvjEpTynGe6_IKvI0cbG5WjI1MVzMgv9oK6LI2zlXqW8iP0N7607p8jPCozEVdKYyRoQMjLrQsA09ehC6yoebVaHSIRNBJypeKL-kOmDhESqPA9HOdaGa3bm8aZaecM9dcOAVo7ybguIFIN1566mfQGjzi0c2G9QTd7v6sx2hvc7ktnwJ73-QnDPMnaN9yg0X4GyzD1pA
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=OP0033+FIBROBLAST+GENE%2C+FKBP7+INDUCED+BY+Ca2%2B+DEPENDENT+ER+STRESS+ASSOCIATED+WITH+CLINICAL+OUTCOME+IN+RHEUMATOID+ARTHRITIS+AND+CROHN%E2%80%99S+DISEASE%3B+MULTI-CENTRE+GWAS+AND+FUNCTIONAL+STUDIES&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Maurits%2C+M.P.&rft.au=Cameron%2C+A.&rft.au=Jelinsky%2C+S.&rft.au=Bl%C3%BCml%2C+S.&rft.date=2024-06-01&rft.issn=0003-4967&rft.volume=83&rft.spage=28&rft.epage=29&rft_id=info:doi/10.1136%2Fannrheumdis-2024-eular.2788&rft.externalDBID=n%2Fa&rft.externalDocID=10_1136_annrheumdis_2024_eular_2788
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon